RxDoctor Payments Data

Mark Blumberg, MD

Dermatology · Springfield, MANPI 1588662019

Payments from drug & device makers

$2,251in general payments, 2019–2025

Across 133 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$790
  • UCB, Inc.$406
  • E.r. Squibb & Sons, L.L.C.$401
  • Arcutis Biotherapeutics, Inc.$150
  • Lilly USA, LLC$141
  • Novartis$94
  • plus $270 from 7 others

What the payments were for

  • Food & beverage$1,83481%
  • Education$41719%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,251 in reported general payments places this provider in the 60th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$518,537
Medicare patients
1,437
Services billed
6,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa15$299,754
Dupixent PenDupilumab54$227,940
CibinqoAbrocitinib18$165,044
Enbrel SureclickEtanercept11$159,802
RinvoqUpadacitinib24$149,107
OtezlaApremilast24$102,365
EnbrelEtanercept11$92,466
ZoryveRoflumilast17$14,299
Clobetasol Propionate186$8,272
Fluorouracil145$6,764
Betamethasone Dipropionate145$6,120
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc62$4,782
Metronidazole62$3,816
Triamcinolone Acetonide197$2,788
Acitretin11$2,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$24$194,83135 claims
PfizerCibinqo$50$165,04418 claims
AbbVieRinvoq$53$149,10724 claims
Arcutis Biotherapeutics, Inc.Zoryve$150$14,29917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →